- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Elaine Siegfried Addresses Patient-Centered Therapeutic Management for Atopic Dermatitis
Elaine Siegfried, MD, professor of pediatrics and dermatology, Saint Louis University Health Sciences Center, discusses therapeutic management considerations for dermatologists in consulting with diverse patients with atopic dermatitis.
Shared decision-making is important to ensure patients with atopic dermatitis (AD) know how to use treatments properly and have an understanding of the associated side effects, said Elaine Siegfried, MD, professor of pediatrics and dermatology, Saint Louis University Health Sciences Center.
Transcript
What considerations should be top of mind for dermatologists managing the care of diverse patients with AD, both in the pediatric and adult setting?
I think it's really important to pay attention to shared decision-making for treatments. Patients have to understand, first and foremost, how to use treatment, and then they also have to get access to that treatment. So, out-of-pocket costs play a big role and just being able to use the medications.
Now, when we talk about more aggressive systemic treatment, the side effect profile has to be explained in great detail, and people have to be understanding of that. And then for the biologic treatments, those are subcutaneous injections, so people have to be willing to do that as well. Although, I find that to be probably the least problematic of all the considerations.
Empowering Teams Begins With Human Connection: Missy Hopson, PhD
April 16th 2025Missy Hopson, PhD, Ochsner Health, discussed in detail the challenges of strengthening the patient-centered workforce, the power of community reputation for encouraging health care careers, and the influence of empowered workforces on patient outcomes.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
SGLT2 Inhibitors Show Renal Benefits in HF and CKD as Prescribers Target Uptake Gaps
April 15th 2025Abstracts featured at the National Kidney Foundation Spring Clinical Meeting highlighted the renoprotective benefits of SGLT2 inhibitors in heart failure and diabetic kidney disease while emphasizing the need for strategies to increase their uptake in primary care.
Read More
Lifestyle Interventions, Statins, Among Keys to Mitigating CVD Risk in MASLD/MASH
April 15th 2025A recent review highlights the gaps in clinical guidelines and treatment approaches for metabolic dysfunction-associated steatohepatitis (MASH) and looks ahead to the future promise of glucagon-like peptide 1 (GLP-1) receptor agonists for liver conditions.
Read More
